BridgeBio Pharma (BBIO) Reports Q3 Loss, Beats Revenue Estimates

BridgeBio Pharma (BBIO) came out with a quarterly loss of $0.95 per share versus the Zacks Consensus Estimate of a loss of$ 0.88. This compares to a loss of $0.86 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -7.95%. A quarter ago, it was expected that this rare disease drug developer would post a loss of$ 0.83 per share when it actually produced a loss of $0.95, delivering a surprise of -14.46%.Over the last four quarters, ...